Skip to main content
Dr. Lal Pathlabs Limited logo

Dr. Lal Pathlabs Limited — Investor Relations & Filings

Ticker · LALPATHLAB ISIN · INE600L01024 LEI · 984500E8E9CY102B9718 BSE.NS Human health and social work activities
Filings indexed 1,098 across all filing types
Latest filing 2024-02-01 Regulatory Filings
Country IN India
Listing BSE.NS LALPATHLAB

About Dr. Lal Pathlabs Limited

https://www.lalpathlabs.com/

Dr. Lal Pathlabs Limited is a provider of diagnostic and related healthcare tests and services. The company offers a comprehensive range of clinical laboratory tests and profiles used for prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. Its service portfolio encompasses pathology, including biochemistry, hematology, clinical pathology, histopathology, and molecular diagnostics, as well as radiology services such as X-ray, ultrasound, and CT scans. The organization operates an extensive network of laboratories, patient service centers, and pick-up points, utilizing advanced automated systems and standardized processes. Key offerings include specialized wellness packages and home sample collection. The company maintains high quality standards through international and national accreditations, serving a diverse patient base and healthcare providers with a focus on accuracy and timely reporting.

Recent filings

Filing Released Lang Actions
Record Date
Regulatory Filings
2024-02-01 English
Dividend Updates
Regulatory Filings
2024-02-01 English
Dividend
Regulatory Filings
2024-02-01 English
Financial Result Updates
Regulatory Filings
2024-02-01 English
Board Meeting — DR. LAL PATH LABS LTD. has informed the Exchange about Board Meeting to be held on 01-Feb-2024 to consider and approve the Quarterly Unaudited Financial results of the Company for the…
Regulatory Filings
2024-01-25 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notice from Dr. Lal PathLabs Limited informing the stock exchanges about a scheduled Board Meeting to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2023, and to consider a proposal for an interim dividend. The document references Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of events or information by listed entities. The document is short (1937 characters) and serves as an announcement of an upcoming board meeting and financial results approval, not the financial results report itself. It also mentions the closure of the trading window in line with insider trading regulations. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain actual financial data or detailed financial statements. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-01-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.